What the DOJ’s 2026 Corporate Enforcement Policy update means for compliance teams
Learn more about the Department of Justice's 2026 update to its Corporate Enforcement Policy, and how AI-enabled communications monitoring can help you stay ahead of regulatory enforcement by detecting and flagging misconduct before a whistleblower does.
What the DOJ’s shortened FCA review timeline means for healthcare and life sciences organizations
A new memorandum compresses FCA reviews from years to months, leaving organizations far less runway to investigate, respond to, and comply with DOJ inquiries.
Now you see it, now you don’t – Why ephemeral messaging capture remains critical for compliance
Regulators like the SEC, CFTC, and DOJ continue to expect firms to maintain proactive compliance programs that support investigations and protect against fraud, which includes managing the use of disappearing messages. We explore the compliance implications of ephemeral messaging and outline practical steps to mitigate risk and meet regulatory obligations.
How to bring pharma sales reps’ communications into compliance
Pharma sales reps operate in high-pressure environments where they're judged on availability and responsiveness. Organizations have invested heavily in tools to support field teams, but that efficiency pressures creates a persistent temptation to cut corners on compliant communications.
Home health care provider pays $34 million after self-disclosing potential FCA violations
The settlement comes after Traditions Health submitted two self-disclosures of billing practices that potentially violated the Stark Law and Anti-Kickback Statute.
How will ChatGPT for Healthcare affect compliance operations?
Without clear guidelines on how to use generative AI tools, organizations must tread carefully to avoid compliance violations.
What advice does the DOJ have for pharma compliance teams?
The DOJ assistant attorney general emphasized proactive self-disclosure and hinted at how pharmaceuticals can best prepare for new trends in enforcement.
The business case for mobile device compliance in healthcare and life sciences
Learn how your organization can implement a mobile device compliance solution to stay audit-ready and catch noncompliant conduct early.
Personal devices in crisis? Risks vs. rewards of BYOD policies in pharmaceuticals
Pharmaceutical companies face a tough choice between enabling BYOD or issuing corporate devices. Understand the risks, rewards, and compliance factors of both.
Regulatory Wrap Episode 71: FDA takes aim at pharma companies’ social media activity
In Regulatory Wrap for the week to October 3, Ryan Thaxton explores the growing spotlight on pharma companies’ social media activity.
FDA takes aim at pharmaceuticals’ social media activity
The FDA is turning its eye towards pharmaceuticals’ social media use. Review the laws and regulations triggering FDA warning letters and how to stay compliant.